Scholarlink

<p>Transmembrane protein 59-like (TMEM59L) has been implicated in malignant tumors; however, its role in colon adenocarcinoma (COAD) remains poorly understood. This study aimed to investigate the diagnostic and prognostic potential of TMEM59L in COAD, explore its association with the tumor microenvironment (TME) and potential implications for immunotherapy response. TMEM59L expression was analyzed in COAD tissue and serum samples using data from TCGA and GEO. Validation was conducted through immunohistochemistry (tissue) and ELISA (serum). Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis; prognostic relevance was evaluated with Kaplan–Meier survival analysis, Cox regression, and nomograms. Functional enrichment analyses were performed to identify associated pathways. Immune cell infiltration was estimated using ssGSEA and single-cell data from TISCH. Immunotherapy response was predicted based on TIDE scores. In vitro, TMEM59L-overexpressing HCT116 cells were used to assess proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) using colony formation, Transwell, qPCR, and western blot assays. TMEM59L expression was significantly downregulated in COAD tissues but elevated in serum samples. High tissue expression was associated with advanced tumor stage and poorer overall survival. Genes co-expressed with TMEM59L were enriched in cancer-related and immune-regulatory pathways. Although TMEM59L expression correlated with increased immune infiltration and immune checkpoint gene expression, high levels predicted poorer response to immunotherapy. Cellular experiments demonstrated that TMEM59L overexpression enhanced proliferation, migration, invasion, and induced EMT (decreased E-cadherin; increased N-cadherin, VE-cadherin, and MMP14) in HCT116 cells. TMEM59L shows promise as a diagnostic and prognostic biomarker in COAD, with potential roles in modulating the TME, EMT, and immunotherapy response.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of TMEM59L as a potential diagnosis, prognosis and immunotherapy biomarker for colon adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月19日

查看全文
  • Wenjun Wang,
  • Wenting Jia,
  • Yingying Du,
  • Dan Zhao,
  • Chang Shi

摘要

Transmembrane protein 59-like (TMEM59L) has been implicated in malignant tumors; however, its role in colon adenocarcinoma (COAD) remains poorly understood. This study aimed to investigate the diagnostic and prognostic potential of TMEM59L in COAD, explore its association with the tumor microenvironment (TME) and potential implications for immunotherapy response. TMEM59L expression was analyzed in COAD tissue and serum samples using data from TCGA and GEO. Validation was conducted through immunohistochemistry (tissue) and ELISA (serum). Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis; prognostic relevance was evaluated with Kaplan–Meier survival analysis, Cox regression, and nomograms. Functional enrichment analyses were performed to identify associated pathways. Immune cell infiltration was estimated using ssGSEA and single-cell data from TISCH. Immunotherapy response was predicted based on TIDE scores. In vitro, TMEM59L-overexpressing HCT116 cells were used to assess proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) using colony formation, Transwell, qPCR, and western blot assays. TMEM59L expression was significantly downregulated in COAD tissues but elevated in serum samples. High tissue expression was associated with advanced tumor stage and poorer overall survival. Genes co-expressed with TMEM59L were enriched in cancer-related and immune-regulatory pathways. Although TMEM59L expression correlated with increased immune infiltration and immune checkpoint gene expression, high levels predicted poorer response to immunotherapy. Cellular experiments demonstrated that TMEM59L overexpression enhanced proliferation, migration, invasion, and induced EMT (decreased E-cadherin; increased N-cadherin, VE-cadherin, and MMP14) in HCT116 cells. TMEM59L shows promise as a diagnostic and prognostic biomarker in COAD, with potential roles in modulating the TME, EMT, and immunotherapy response.